LYEL
What one share of Lyell Immunopharma holds
Pharmaceutical Preparations
We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors.
Lyell Immunopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$11.82 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$6.37 |
| Cash and investments | $9.74 |
| Book value | $9.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$476.61 | $59.12 | $86.30 | — | −$409.31 |
| 2020 | — | −$313.85 | $77.66 | −$320.34 | — | −$375.76 |
| 2021 | — | −$36.82 | $9.64 | −$28.22 | — | $76.61 |
| 2022 | — | −$14.82 | $1.97 | −$15.69 | — | $66.78 |
| 2023 | $0.01 | −$18.70 | $0.21 | −$13.26 | — | $51.58 |
| 2024 | $0.00 | −$26.23 | $0.04 | −$12.46 | — | $25.97 |
| 2025 | $0.00 | −$16.06 | $0.05 | −$8.82 | — | $11.68 |